EDITORIAL
Estimands—new statistical principle or the emperor's new clothes?
First published: 14 December 2016
No abstract is available for this article.
REFERENCES
- 1G. K. Rosenkranz, Ther. Innov. Regul. Sci. 2013, 47, 455.
- 2 ICH: Final Concept Paper E9(R1): addendum to statistical principles on choosing appropriate estimands and defining sensitivity analyses in clinical trials, 2014.
- 3
National Research Council, The Prevention and Treatment of Missing Data in Clinical Trials, The National Academies Press, Washington DC 2010.
- 4A. Gelman, J. B. Carlin, H. S. Stern, D. B. Rubin, Bayesian Data Analysis, 2nd ed., Chapman & Hall/CRC, Boca Raton 2004.
- 5G. W. Imbens, D. B. Rubin, Causal Inference for Statistics, Social, and Biomedical Sciences, Cambridge University Press, New York, 2015.
- 6Akacha M, Bretz F, Ohlssen D, Rosenkranz G, Schmidli H. Estimands and their role in clinical trials. Summer Issue of the American Statistical Association's Biopharmaceutical Section Report. 2015, 22, 1.
- 7A. Phillips, J. Abellan-Andres, A. Soren, F. Bretz, C. Fletcher, L. France, A. Garrett, R. Harris, M. Kjaer, O. Keene, D. Morgan, M. O'Kelly, J. Roger, Pharm. Stat. 2017, 16, 6. DOI: 10.1002/pst.1745.
- 8A. K. Leuchs, A. Brandt, J. Zinserling, N. Benda, Pharm. Stat. 2017, 16, 12. DOI: 10.1002/pst.1791.
- 9T. Permutt, F. Li, Pharm. Stat. 2017, 16, 20. DOI: 10.1002/pst.1768.
- 10C. Mallinckrodt, G. Molenberghs, S. Rathmann, Pharm. Stat. 2017, 16, 29. DOI: 10.1002/pst.1765.
